Clinical-stage cancer immunotherapy company Compugen Ltd. announced on Thursday that it will present the latest progress from its MAIA-ovarian trial in a poster presentation at the 2026 European Society for Medical Oncology (ESMO) Gynecological Cancers Congress.

The congress is scheduled to take place in Copenhagen, Denmark from June 17 to 19.

The presentation will focus on the safety and efficacy of COM701 as a maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer.

COM701 is a potential first-in-class anti-PVRIG antibody. The trial is named MAIA-ovarian, with MAIA standing for "Maintenance Immunotherapy with Anti-PVRIG Antibody."

According to the company, the poster is titled "MAIA-ovarian (NCT06888921) Adaptive Platform Clinical Trial: Evaluating the Safety and Efficacy of COM701 as Maintenance Therapy in Recurrent Platinum-Sensitive Ovarian Cancer."

The poster, numbered 170, will be presented by Dr. Oladapo Yeku from Massachusetts General Hospital in the U.S. between 12:45 PM and 1:30 PM local time on June 18.

The trial design is a double-blind, randomized, placebo-controlled study planning to randomly assign 60 patients in a 2:1 ratio to receive either COM701 or a placebo.

The company has previously stated that, based on historical data, the expected benchmark for progression-free survival is approximately six months, and it considers an improvement of three months over placebo to be clinically meaningful for patients.

An interim analysis for this trial is anticipated to be completed in the first quarter of 2027.

In prior research, a triple therapy combining COM701 with PD-1 and TIGIT inhibitors has shown durable responses in patients with platinum-resistant ovarian cancer, who typically do not respond to immunotherapy.

The President and Chief Executive Officer of Compugen stated that with all clinical sites for the MAIA-ovarian trial continuing to advance patient enrollment, the company remains on track for the interim analysis in Q1 2027, which could represent a significant turning point for COM701 as a maintenance therapy.